These findings support the view that the D1R–D3R heteromer may act by improving the recognition and signaling of D1Rs, particularly concerning D1R-mediated locomotor activity, and when heightened by chronic l-DOPA therapy, may also contribute to the onset of dyskinesias in parkinsonian patients [236]. This evidence concerns the gene DRD1 and Dyskinesia.